Should I buy Inspire Medical Systems, Inc. (INSP) stock or is it too late?
No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.
Firm-by-firm track record on Inspire Medical Systems, Inc.
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Wells Fargo | 75 % | +79.7 % | 8 | $56 -8% |
| Stifel | 71 % | +74.5 % | 7 | $65 +7% |
| Piper Sandler | 44 % | +9.6 % | 18 | $60 -1% |
| JP Morgan | 40 % | -3.1 % | 5 | $60 -1% |
| Mizuho | 17 % | -9.4 % | 6 | $65 +7% |
| Truist Securities | 18 % | -14.4 % | 17 | $62 +2% |
| Baird | 17 % | -36.6 % | 6 | $59 -3% |
| Morgan Stanley | 0 % | -45.5 % | 5 | $130 +114% |
✅ Reasons to believe
- Few solid positives from analysts right now: of 11 ratings, only 4 buys, and the median price target ($60) is -1% below the price ($61). Caution prevails.
⚠️ Reasons to hesitate
- Even the most reliable firm on INSP, Wells Fargo (75% hit rate, 8 scored calls), only targets $56 (call made on May 5, 2026, maturing on May 5, 2027) (-8%) in its most recent call, and $145 (call made on January 14, 2026, maturing on January 14, 2027) (+138%) in the one coming due soonest. The stock may already have run past its target.
- The consensus is not unanimous: of 11 ratings, 7 are neutral.
- Limited upside: the median target is only -1% from the current price.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on INSP
Median target $60 (-1%) · 11 ratings · Hold consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Inspire Medical Systems, Inc. now?
We won't decide for you. The facts: 36% of analysts rate it a buy, median target $60 (-1%), and Wells Fargo (most reliable on INSP, 75%) targets $56. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Inspire Medical Systems, Inc.?
The stated upside is small: the median target ($60) sits just -1% from the price ($61) (most reliable on INSP: Wells Fargo, 75%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Inspire Medical Systems, Inc. still worth investing in?
It depends on the gap between the price ($61) and its estimated value: analysts target $60 on median (-1%), with 36% buys (most reliable on INSP: Wells Fargo, 75%). Cross-check with their real reliability on INSP and the cautions above. Information, not advice.
What's the main risk in buying INSP?
Even the most reliable firm on INSP, Wells Fargo (75% hit rate, 8 scored calls), only targets $56 (call made on May 5, 2026, maturing on May 5, 2027) (-8%) in its most recent call, and $145 (call made on January 14, 2026, maturing on January 14, 2027) (+138%) in the one coming due soonest. The stock may already have run past its target.
→ Go deeper: the full Inspire Medical Systems, Inc. profile (consensus, analyst reliability, price target, performance).